30 Nov 2021 07:00
REDX PHARMA PLC
("Redx" or the "Company")
Redx to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference
Alderley Park, UK, 30 November 2021 - Redx Pharma (AIM: REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, announces that Lisa Anson, Chief Executive Officer, and Peter Collum, Chief Financial Officer, will be participating at the Piper Sandler 33rd Annual Virtual Healthcare Conference, 30 November to 2 December.
A pre-recorded presentation by Lisa Anson can be accessed via the following link: https://bit.ly/3CSvvSV
For further information, please contact: |
|
|
|
Redx Pharma Plc
UK Headquarters Lisa Anson, Chief Executive Officer | T: +44 (0)1625 469 918 |
Karl Hård, Head of Investor Relations k.hard@redxpharma.com |
|
US Office Peter Collum, Chief Financial Officer |
|
|
|
SPARK Advisory Partners (Nominated Adviser) | T: +44 (0)203 368 3550 |
Matt Davis/ Adam Dawes |
|
|
|
WG Partners LLP (Joint Broker) | T: +44 (0)203 705 9330 |
Claes Spång/ Satheesh Nadarajah/ David Wilson |
|
|
|
Panmure Gordon (UK) Limited (Joint Broker) | T: +44 (0)207 886 2500 |
Rupert Dearden/ Freddy Crossley/ Emma Earl |
|
|
|
FTI Consulting | T: +44 (0)203 727 1000 |
Simon Conway/ Ciara Martin |
|
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, commenced a Phase 2 programme in November 2021. The Company's selective ROCK2 inhibitor product candidate, RXC007, is in development for idiopathic pulmonary fibrosis and commenced a Phase 1 clinical trial in June 2021. Initial results were reported in October 2021, with full Phase 1 results expected in 2022.
The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by the two wholly-owned clinical-stage product candidates and rapidly expanding pipeline, but also by the four strategic transactions from which has emerged the most advanced product candidate pirtobrutinib (RXC005, LOXO-305), a BTK inhibitor now in Phase 3 clinical development by Eli Lilly following its acquisition of Loxo Oncology. In addition, Redx has forged pre-clinical collaborations with AstraZeneca and Jazz Pharmaceuticals.
To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/